Skip to main content
S 932 119th Congress Senate Health

Give Kids a Chance Act of 2025

Introduced: March 11, 2025 See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 11, 2025
Introduced in Senate
Mar 11, 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Give Kids a Chance Act of 2025

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.

GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.

What's happening now March 11, 2025

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 5
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 181

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

See all 181 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). S. 932: Give Kids a Chance Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-S-932/
MLA
"S. 932: Give Kids a Chance Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-932/.
Bluebook (legal)
S. 932, 119th Cong. (2026), https://openamerica.io/bill/119-S-932/.
Markdown link
[S. 932: Give Kids a Chance Act of 2025](https://openamerica.io/bill/119-S-932/)
Report a problem